当前位置: 首页 >> 检索结果
共有 6972 条符合本次的查询结果, 用时 7.9833447 秒

6921. Aminosalicylates and COVID-19: Facts or Coincidences?

作者: Fernando Magro.;Claudia Camila Dias.;Manuela Morato.
来源: Gastroenterology. 2021年160卷5期1884-1885页

6922. The Dilemma in the Management of Gastrointestinal Bleeding During the COVID-19 Pandemic.

作者: Enrik John T Aguila.;Ian Homer Y Cua.;Nikko Theodore V Raymundo.
来源: Gastroenterology. 2021年160卷5期1889-1890页

6923. Mild Pancreatic Enzyme Elevations in COVID-19 Pneumonia: Synonymous With Injury or Noise?

作者: Aditya Ashok.;Mahya Faghih.;Vikesh K Singh.
来源: Gastroenterology. 2021年160卷5期1872页

6924. COVID-19 and Future Implications for Gastroenterology Trainees.

作者: Lady Katherine Mejía Pérez.;Neel Sharma.
来源: Gastroenterology. 2021年160卷6期2198-2199页

6925. SARS-CoV-2 RNA Detection in Gastrointestinal Sample Displays Poor Performance.

作者: Xiao-Cun Xing.;Bei Qi.;Kai Deng.
来源: Gastroenterology. 2021年160卷3期972-973.e1页

6926. Hoarseness After Endoscopic Retrograde Cholangiopancreatography.

作者: Kazunari Nakahara.;Yosuke Michikawa.;Fumio Itoh.
来源: Gastroenterology. 2021年160卷1期e15-e16页

6927. An Infant with Acute Onset of Nonbilious Emesis.

作者: Natascha S Sandy.;Peter Christopher Church.;Tanja Gonska.
来源: Gastroenterology. 2021年160卷1期e9-e10页

6928. Recurrent Anemia and Hematochezia: When Total Enteroscopy with Motorized Spiral Enteroscopy Gives the Answer.

作者: Michael Fernandez Y Viesca.;Nicky D'Haene.;Marianna Arvanitakis.
来源: Gastroenterology. 2021年160卷1期e6-e8页

6929. A Remote Cause of Epigastric Pain.

作者: John Julian Harvey.;Ralley Elizabeth Prentice.;Chow Heok P'ng.
来源: Gastroenterology. 2021年160卷1期e13-e14页

6930. The Unexpected Perpetrator: A Story of Indigestion.

作者: Ishita Dhawan.;Sonali Palchaudhuri.;Gregory G Ginsberg.
来源: Gastroenterology. 2021年160卷1期e11-e12页

6931. An Unusual Cause of Dysphagia.

作者: Ming-Chang Tsai.;Ching-Tai Lee.;Wen-Lun Wang.
来源: Gastroenterology. 2021年160卷1期e17-e18页

6932. Intestinal perforations after endoscopic retrograde cholangiopancreatography in the USA: a 16-year study using the National Inpatient Sample.

作者: Babatunde Olaiya.;Douglas G Adler.
来源: Minerva Gastroenterol (Torino). 2021年67卷3期276-282页
Intestinal perforation is a rare but feared complication of ERCP. In this study, we identify patient and hospital factors for ERCP related intestinal perforation using a large national database. We also examine the effects of intestinal perforations on hospital outcomes.

6933. Management of nutritional consultations in local clinics during SARS-CoV-2 pandemic.

作者: Francesca Accardi.;Isabella Cammarata.;Fulvia Canaletti.;Ilaria Bachini.;Anna Demagistris.
来源: Minerva Gastroenterol (Torino). 2023年69卷3期438-440页

6934. Non-cirrhotic portal hypertension in inflammatory bowel disease.

作者: Adil S Mir.;Dario Sorrentino.
来源: Minerva Gastroenterol (Torino). 2023年69卷2期291-299页
With the increasing incidence and prevalence of inflammatory bowel diseases (IBD), its complications and associated morbidity also continue to rise. One of these is non-cirrhotic portal hypertension. There is an increasing need of recognizing and understanding the pathophysiology of this condition in the clinical setting of IBD, especially in long standing cases. Due to multiple potential factors, patients with IBD appear to be at a higher risk of developing portal hypertension even in the absence of liver cirrhosis. Portal hypertension is usually diagnosed when complications (such as ascites, variceal bleeding) develop, especially when patients have already experienced multiple complications of the disease. Hence, a high level of vigilance for the detection of portal hypertension at an early stage is needed. This review discusses the known epidemiology, clinical characteristics, clinical presentation, modalities of diagnosis and the potential treatments of the different forms of non-cirrhotic portal hypertension associated with IBD. The concomitant presence of portal hypertension can significantly impact the overall clinical picture and disease burden in IBD. Hence, increased awareness of this condition at an early stage might help tailor a comprehensive and individualized therapeutic plan of care for these patients.

6935. Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?

作者: Vlad Ratziu.;Scott L Friedman.
来源: Gastroenterology. 2023年165卷1期5-10页

6936. Roles of Clinical Pharmacists in Caring for Patients With Inflammatory Bowel Disease During COVID-19.

作者: Shubha Bhat.;Francis A Farraye.;Alan Moss.
来源: Gastroenterology. 2021年160卷5期1880页

6937. COVID-19 and Long-term Planning for Procedure-based Specialties During Extended Mitigation and Suppression Strategies.

作者: Smita Rouillard.;Vincent X Liu.;Douglas A Corley.
来源: Gastroenterology. 2021年160卷1期4-9页

6938. The Usefulness of Fecal Calprotectin in the era of the COVID-19 Pandemic.

作者: Sheena Mago.;Haleh Vaziri.;Micheal Tadros.
来源: Gastroenterology. 2021年160卷7期2623-2625页

6939. Focusing on Gastrointestinal Symptoms in COVID-19 Is Far From Enough.

作者: Yuzhi Liu.;Lingya Xiang.;Kai Deng.
来源: Gastroenterology. 2021年160卷4期1429-1430.e2页

6940. Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic.

作者: Paulo Gustavo Kotze.;Laurent Peyrin-Biroulet.;Silvio Danese.
来源: Gastroenterology. 2021年160卷1期472-473页
共有 6972 条符合本次的查询结果, 用时 7.9833447 秒